<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian J Linder, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nelson J Chao, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mrinal M Gounder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven E Schild, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemorrhagic cystitis (HC) is a sterile cystitis that is characterized by gross hematuria. It is most common in patients treated with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         and high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in the setting of bone and soft tissue sarcoma and hematopoietic cell transplantation, or as a late toxicity of pelvic radiation therapy (RT) when the bladder is within the radiation treatment field.
        </p>
        <p>
         The etiology, manifestation, and treatment of HC secondary to systemic chemotherapy and RT will be reviewed here. Acute infectious cystitis and cystitis caused by intravesical instillation of Bacillus Calmette-Guerin (BCG), used in the management of urothelial bladder cancers, as well as BK-virus-associated hemorrhagic cystitis are discussed separately. HC in patients receiving prolonged oral or intermittent intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         as an immunosuppressant for rheumatologic conditions such as autoimmune disease and vasculitis is also discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2973.html" rel="external">
          "Infectious complications of intravesical BCG immunotherapy", section on 'Localized disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases", section on 'Hemorrhagic cystitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Prevention of drug-induced cystitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8280.html" rel="external">
          "Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections", section on 'Hemorrhagic cystitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">
          "Overview of infections following hematopoietic cell transplantation", section on 'Hemorrhagic cystitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2518800431">
         <span class="h1">
          ETIOLOGY AND PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2153718717">
         <span class="h2">
          Chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various chemotherapeutic agents, including
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">
          dacarbazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         , and
         <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">
          cabazitaxel
         </a>
         , can cause either nonhemorrhagic or hemorrhagic cystitis (HC)  (
         <a class="graphic graphic_table graphicRef66805" href="/z/d/graphic/66805.html" rel="external">
          table 1
         </a>
         ). HC is most frequently described in patients receiving the oxazaphosphorine alkylating agents ifosfamide and cyclophosphamide [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          Ifosfamide
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         are approved for use in a variety of malignancies, both in children and adults. Cyclophosphamide is also used as a component of conditioning regimens prior to hematopoietic cell transplantation and as an immunosuppressant in a variety of rheumatologic (eg, autoimmune disease, vasculitis), nephrologic (eg, minimal change nephrotic syndrome), dermatologic (eg, refractory pemphigus), and neurologic (eg, relapsing/remitting multiple sclerosis) conditions. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">
          "Minimal change disease: Treatment in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15304.html" rel="external">
          "Management of refractory pemphigus vulgaris and pemphigus foliaceus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">
          "Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"
         </a>
         .)
        </p>
        <p>
         For patients treated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , HC is a complex inflammatory response that is induced by a toxic metabolite (acrolein), with subsequent activation of immunocompetent cells and release of many proinflammatory agents [
         <a href="#rid3">
          3,4
         </a>
         ]. During hepatic metabolism of both cyclophosphamide and ifosfamide, acrolein is generated, filtered by the kidneys, and concentrated in the bladder [
         <a href="#rid5">
          5,6
         </a>
         ]. Acrolein is a reactive, unsaturated aldehyde that causes cell death through upregulation of reactive oxygen species, and that activates inducible nitric oxide synthase, leading to the production of nitric oxide [
         <a href="#rid7">
          7,8
         </a>
         ]. Both reactive oxygen species and nitric oxide produce peroxynitrite, which attacks cellular macromolecules (lipids and proteins) and causes DNA strand breaks that trigger overactivity of DNA repair enzymes [
         <a href="#rid9">
          9,10
         </a>
         ]. Reactive oxygen species also allow nuclear factor kappa B (NF-kB) to enter the nucleus and turn on transcription of genes encoding proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin 11 (IL-11) [
         <a href="#rid10">
          10
         </a>
         ]. The end result is cessation of protein production and damage to the integrity of the urothelium, with morphologic and histologic evidence of swelling, bleeding, and ulceration of the bladder mucosa.
        </p>
        <p class="headingAnchor" id="H4058797716">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation cystitis is a late complication of pelvic radiation therapy (RT) that can occur months to years after RT is administered. (See
         <a class="local">
          'Radiation therapy'
         </a>
         below.)
        </p>
        <p>
         After administration of pelvic RT that includes the bladder, the bladder mucosa is initially edematous and friable. Later, there is progressive endarteritis (which leads to obliteration of the submucosal vasculature, with subsequent ischemia and reperfusion injury) and fibrosis of the mucosa and submucosa, with the development of dilated, fragile telangiectatic blood vessels that tend to bleed [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H410132150">
         <span class="h1">
          INCIDENCE AND RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H1517415674">
         <span class="h2">
          Ifosfamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hemorrhagic cystitis (HC) seen with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         therapy was identified in early clinical trials and recognized as a dose-limiting toxic effect [
         <a href="#rid12">
          12-14
         </a>
         ]. In early trials, large single ifosfamide doses produced gross hematuria in 100 percent of patients [
         <a href="#rid15">
          15
         </a>
         ]. In a later study using ifosfamide 5 to 7 g/m
         <sup>
          2
         </sup>
         divided into four to six doses given over two to three days without specific uroprotection, the incidence of HC was 18 percent (versus 6 percent with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         1 to 1.2 g/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid16">
          16
         </a>
         ]. In other studies, the reported overall incidence of HC among patients treated with fractionated dosing of ifosfamide without urothelial protection ranges from 18 to 40 percent [
         <a href="#rid14">
          14,17
         </a>
         ]. In contrast, when ifosfamide is administered with the uroprotectant
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         , gross hematuria is uncommon (occurring in &lt;5 percent of cases), and microscopic hematuria alone occurs in 5 to 18 percent of courses [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
         Prophylactic
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         is recommended for all patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         for cancer [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="local">
          'Mesna'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H564616439">
         <span class="h2">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         HC was described shortly after the introduction of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         to clinical use in 1958; it affected 10 to 40 percent of patients, and it sometimes abated on withdrawal of the drug [
         <a href="#rid24">
          24
         </a>
         ]. The incidence of HC is higher in individuals who receive higher individual (as in the setting of hematopoietic cell transplantation [HCT]) and larger cumulative cyclophosphamide doses (such as in prolonged oral therapy for rheumatologic conditions) [
         <a href="#rid25">
          25
         </a>
         ]. However, cases are described after single intravenous cyclophosphamide doses of 500 to 600 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid26">
          26,27
         </a>
         ]. (See
         <a class="local">
          'Patients undergoing hematopoietic cell transplantation'
         </a>
         below and
         <a class="local">
          'Nontransplant settings'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3897987572">
         <span class="h3">
          Patients undergoing hematopoietic cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients receiving a cyclophosphamide-containing conditioning regimen prior to HCT are at risk for HC. In several reports, the cumulative incidence is 8 to 17 percent [
         <a href="#rid28">
          28-30
         </a>
         ]. HC is reported following both autologous and allogenic transplantation, and it is more common after a myeloablative regimen than a reduced-intensity conditioning regimen [
         <a href="#rid29">
          29
         </a>
         ]. The median duration of HC in one study was 27 days [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Besides the use of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in a conditioning regimen, other potential contributory factors for HC in these patients include viral infection with BK/JC polyomavirus, adenovirus, or cytomegalovirus [
         <a href="#rid31">
          31-35
         </a>
         ], and higher doses of
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         . As an example, a strong association between BK viruria and long-lasting HC after HCT has been described, which might also explain why some patients get HC after a cyclophosphamide-containing conditioning regimen for HCT, while others do not [
         <a href="#rid29">
          29,36
         </a>
         ]. Early posttransplant HC (defined as occurring within 72 hours of the preparative regimen) is more frequently associated with high-dose cyclophosphamide, while later HC more often results from viral infections, such as BK polyomavirus and adenovirus type 11. (See
         <a class="local">
          'Viral infections'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2594736033">
         <span class="h3">
          Nontransplant settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, the incidence of HC is higher in individuals who receive higher individual and larger cumulative
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         doses [
         <a href="#rid25">
          25
         </a>
         ]. Although cases are described after single intravenous cyclophosphamide doses of 500 to 600 mg/m
         <sup>
          2
         </sup>
         , this is uncommon. Given the lower rates of HC with cyclophosphamide as compared with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , and given the dose dependence of HC with cyclophosphamide, use of prophylactic
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         has been considered unnecessary with the "standard" doses of intravenous cyclophosphamide used for cancer treatment outside of the setting of HCT [
         <a href="#rid21">
          21-23
         </a>
         ].
        </p>
        <p>
         The risk of HC and use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         in patients receiving
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for rheumatologic disorders are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases", section on 'Hemorrhagic cystitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3022192851">
         <span class="h3">
          Genetic factors influencing risk with cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients receiving
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , genetic polymorphisms in genes involved with cyclophosphamide metabolism may influence the risk of HC [
         <a href="#rid28">
          28,37
         </a>
         ]. As an example, heterozygosity for the
         <em>
          ALDH3A1*2
         </em>
         allele, which mediates degradation of activated cyclophosphamide metabolites, has been associated with a nearly 12-fold increase in the risk of HC compared with the wild-type
         <em>
          ALDH3A1
         </em>
         variant [
         <a href="#rid37">
          37
         </a>
         ]. Others have found polymorphisms in the drug metabolizing enzymes glutathione S-transferase (GST) and cytochrome P450 2C9 (CYP2C9) to be associated with HC risk in pediatric patients undergoing HCT after a conditioning regimen that included
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         and cyclophosphamide [
         <a href="#rid28">
          28
         </a>
         ]. There are no published data on the genetic factors influencing risk of HC with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         .
        </p>
        <p>
         Despite these data, current practice does not support the routine genotyping of any candidate gene to identify patients who might be at higher risk for HC in order to select more effective prophylactic therapy.
        </p>
        <p class="headingAnchor" id="H3271191073">
         <span class="h2">
          Radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute radiation therapy (RT)-related cystitis occurring during therapy can be a common complication with conventionally dosed pelvic RT, although the incidence is highly variable. It is associated with irritative voiding symptoms (eg, dysuria, frequency, urgency, and nocturia) and bladder spasms, but not usually hematuria. (See
         <a class="medical medical_review" href="/z/d/html/90926.html" rel="external">
          "Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies", section on 'Acute radiation cystitis'
         </a>
         .)
        </p>
        <p>
         HC is reported as a late complication in 6.5 to 9 percent of patients who have received full-dose, standard-fractionation pelvic RT for prostate or gynecologic cancer [
         <a href="#rid38">
          38-40
         </a>
         ], but it is severe in less than 5 percent [
         <a href="#rid41">
          41
         </a>
         ]. The likelihood of developing radiation-induced HC is related to the total RT dose, the dose per fraction, and the volume of the bladder irradiated. Higher total doses of radiation (ie, such as are administered using conformal or intensity-modulated RT) can be associated with focal injury and a higher risk of hematuria or ulceration [
         <a href="#rid42">
          42,43
         </a>
         ]. As an example, in one series of 309 patients receiving intensity-modulated RT for high-risk prostate cancer (78 Gy in 39 fractions), at a median follow-up of one to four months, the most frequently observed grade 2 or higher genitourinary toxicity was hematuria (11 percent), with radiation cystitis observed in the majority [
         <a href="#rid42">
          42
         </a>
         ]. Rates were highest in patients in whom a high volume of the bladder neck was exposed to &gt;75 Gy. In addition to the dose and volume of the bladder irradiated [
         <a href="#rid44">
          44
         </a>
         ], other risk factors include high rates of
         <strong>
          acute
         </strong>
         grade ≥2 genitourinary toxicity [
         <a href="#rid45">
          45
         </a>
         ], use of androgen deprivation therapy, and a history of transurethral resection of the prostate [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SIGNS AND SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of hemorrhagic cystitis (HC) in cancer patients is highly variable, ranging from mild hematuria and bladder irritation (which can be managed with observation or with hydration and bladder irrigation) to gross hematuria with clots and life-threatening persistent hemorrhage. Gross hematuria is suspected because of the presence of pink, red, or brown urine. Notably, this color change does not necessarily reflect severe underlying disease, since as little as 1 mL of blood per liter of urine can induce a visible color change. In more severe cases, the urine is no longer translucent, rather it is thick (with a consistency that is similar to ketchup), and patients may pass blood clots of variable size/volume in their urine  (
         <a class="graphic graphic_picture graphicRef117631" href="/z/d/graphic/117631.html" rel="external">
          picture 1
         </a>
         ). Disorders in hemostasis due to systemic manifestations of cancer or its treatment (eg, thrombocytopenia or disseminated intravascular coagulation), or anticoagulation can exacerbate bleeding in susceptible patients [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         In addition to hematuria, patients may also experience lower urinary tract symptoms, such as urinary urgency, frequent urination of small volumes, the sensation of incomplete bladder emptying, and a painful burning sensation with urination. In men, bladder spasms may produce severe referred pain in the glans penis. While suprapubic discomfort may be encountered, flank or back pain should raise the possibility of upper urinary tract or bladder outlet obstruction. In cases of more severe bleeding, patients may present with urinary retention secondary to blood clots obstructing the bladder neck (also known as "clot retention").
        </p>
        <p>
         For patients receiving
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , bleeding usually develops 24 to 48 hours after a single dose and typically lasts four to five days. The interval between the onset of HC and prior radiation therapy (RT) varies from months to years after treatment [
         <a href="#rid39">
          39,48
         </a>
         ]; HC can appear as late as 10 or 20 years after treatment [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H779158901">
         <span class="h2">
          Grading the severity of hemorrhagic cystitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several investigators and groups, including the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), have used various grading schemes based on the level of intervention required for therapy  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ). Among patients who develop severe HC despite vigorous preventive measures, deaths are reported, although this is extremely rare [
         <a href="#rid5">
          5,51
         </a>
         ].
        </p>
        <p>
         Severity grading criteria for long-term bladder toxicity after RT are also available from the Radiation Therapy Oncology Group (RTOG)  (
         <a class="graphic graphic_table graphicRef117439" href="/z/d/graphic/117439.html" rel="external">
          table 3
         </a>
         ). However, the CTCAE criteria are used more often.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of hemorrhagic cystitis (HC) is based on a typical clinical presentation including hematuria and lower urinary tract symptoms, after excluding other potential causes of the signs/symptoms (such as urinary tract infection, bladder tumor, local tumor extension, and urolithiasis) via a complete hematuria evaluation (ie, urine culture, cystoscopy, urine cytology, upper urinary tract imaging). (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'Initial evaluation'
         </a>
         .)
        </p>
        <p>
         A thorough history is needed to evaluate for likely contributing etiologies (including assessing for any prior urologic diagnoses or surgeries, chemotherapy and radiation therapy [RT] treatments, and anticoagulant, over-the-counter, and nontraditional medication use). An exhaustive history of past and present medications is important since some chemotherapeutic agents may produce cystitis years after exposure (eg,
         <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">
          busulfan
         </a>
         ) [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3357294663">
         <span class="h2">
          Tempo and location of the evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of HC is guided by the patient's presentation. In mild cases, the evaluation should proceed as mentioned above (ie, urinalysis, urine culture) and can be carried out in an outpatient setting. For severe HC, hospital admission may be appropriate with the initial evaluation, focusing on rapid assessment of hemodynamic stability and ensuring adequate bladder drainage with hyperhydration. Once the patient is stabilized and adequate bladder drainage is secured, further evaluation with cystoscopy, urine cytology, and upper urinary tract imaging can proceed as above to identify contributing etiologies.
        </p>
        <p class="headingAnchor" id="H923064894">
         <span class="h2">
          Components of the diagnostic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The components of the workup are urinalysis and urine culture to rule out bacterial infection in all patients; selected patients may require cystoscopy, urine cytology, and upper urinary tract imaging.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with signs or symptoms of gross hematuria and/or cystitis should undergo examination of the urine sediment and bacterial culture of a clean catch specimen to confirm hematuria and rule out underlying bacterial infection. (See
         <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">
          "Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of infection, if the hematuria is not severe (ie, grade 1  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ) and the temporal onset is immediately following a dose of
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , it is reasonable to pursue hydration, and possibly higher doses of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         , without additional workup. We would repeat the urinalysis four to six weeks after the inciting cause to document resolution, with referral/additional workup if it persists [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For more severe cases or if the diagnosis is in question, cystoscopy is indicated to evaluate for bladder tumors and potentially localize the bleeding. HC is typically characterized on cystoscopy by diffuse oozing of the bladder mucosa with neovascularization and telangiectasias  (
         <a class="graphic graphic_picture graphicRef117630" href="/z/d/graphic/117630.html" rel="external">
          picture 2
         </a>
         ); the presence of a discrete bleeding vessel is less common. In cases of severe bleeding, cystoscopy under anesthesia may also allow for fulguration of bleeding vessels and clot evacuation. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'Cystoscopy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe cases or if the diagnosis is in question, evaluation of the upper and lower urinary tract with computed tomography (CT) urogram (if renal function allows) is needed to evaluate for renal or ureteral tumors, bladder or other pelvic masses, and urolithiasis. In severe HC, this allows for an assessment of the degree of clot burden in the bladder  (
         <a class="graphic graphic_diagnosticimage graphicRef117629" href="/z/d/graphic/117629.html" rel="external">
          image 1
         </a>
         ). If a CT urogram cannot be performed due to contraindications, magnetic resonance (MR) urogram, or renal ultrasound and retrograde pyelograms can be performed [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'CT urography'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral cultures, cytology, and special molecular techniques may be required to demonstrate unusual pathogens in severely immunocompromised patients (eg, after hematopoietic cell transplantation [HCT]). If lesions are present on external genitalia, a smear and culture can be performed for direct fluorescent antibody detection and growth of herpes simplex virus. (See
         <a class="local">
          'Viral infections'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete blood count, serum creatinine, and coagulation parameters (eg, prothrombin and activated partial thromboplastin times) should be assessed at presentation in cases of severe HC.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H171000551">
         <span class="h2">
          Differential diagnosis
         </span>
        </p>
        <p class="headingAnchor" id="H2745669053">
         <span class="h3">
          Gross hematuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The intermittent excretion of red to brown urine can be seen in a variety of clinical conditions other than bleeding into the urinary tract. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H467858842">
         <span class="h3">
          Infectious cystitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infectious agents responsible for cystitis in cancer patients include both bacteria, which commonly cause infections in immunocompetent patients, and more unusual pathogens. (See
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males"
         </a>
         .)
        </p>
        <p>
         Typical urinary pathogens include
         <em>
          Escherichia coli
         </em>
         ,
         <em>
          Proteus
         </em>
         spp,
         <em>
          Klebsiella
         </em>
         spp, and
         <em>
          Staphylococcus saprophyticus
         </em>
         . Coagulase-negative staphylococci can occasionally produce cystitis in patients with indwelling bladder catheters or urinary tract pathology, but they are also frequent contaminants in a poorly collected specimen.
        </p>
        <p>
         Intracellular pathogens such as
         <em>
          Mycoplasma
         </em>
         and
         <em>
          Ureaplasma
         </em>
         are rare causes of cystitis in the cancer patient. Herpes simplex virus can cause urethritis, but rarely cystitis.
         <em>
          Candida albicans
         </em>
         and
         <em>
          Candida glabrata
         </em>
         have been reported to cause cystitis that is often hemorrhagic in severely immunocompromised hosts. In the United States, parasitic pathogens are distinctly uncommon. However,
         <em>
          Schistosoma haematobium
         </em>
         infection should be considered in patients from endemic regions, such as Egypt.
        </p>
        <p>
         In patients with bacterial cystitis, examination of the urine often demonstrates white blood cells and a few red blood cells. However, the absence of white blood cells in a patient who is neutropenic following chemotherapy does not exclude a urinary tract infection. In an immunocompetent host, bacterial colony counts of greater than 100,000 in the urine are considered diagnostic of a urinary tract infection. It is not yet resolved whether this threshold should be lowered in neutropenic patients. (See
         <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">
          "Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">
          "Diagnostic approach to the adult cancer patient with neutropenic fever", section on 'Routine laboratory tests'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3736717956">
         <span class="h4">
          Viral infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         HC is commonly seen following HCT. Among patients undergoing a cyclophosphamide-containing conditioning regimen prior to HCT, early posttransplant HC (defined as occurring within 72 hours of the preparative regimen) is frequently associated with the use of high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , while later HC more often results from viral infections, such as BK polyomavirus (BKPyV) and adenovirus type 11 (AdV-11). (See
         <a class="local">
          'Patients undergoing hematopoietic cell transplantation'
         </a>
         above.)
        </p>
        <p>
         It is hypothesized that virally mediated HC represents the reactivation of a latent form of the virus in the posttransplant period. In one study, recipient seropositivity for AdV-11 was highly predictive for the development of AdV-11-induced HC following allogeneic HCT [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8280.html" rel="external">
          "Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8339.html" rel="external">
          "Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"
         </a>
         .)
        </p>
        <p>
         Viral HC can be dramatic in presentation, but it usually resolves spontaneously within less than two weeks with supportive care including hydration and pain control. Virus culture is rarely used to detect JC polyomavirus (JCPyK) and BKPyV infection outside of a research setting. Cytologic examination can be used to detect urinary shedding of polyomaviruses. The most characteristic abnormality of polyomavirus-infected cells is an enlarged nucleus with a single, large, basophilic intranuclear inclusion [
         <a href="#rid55">
          55,56
         </a>
         ]. The most important aspect of the diagnostic evaluation is to ensure that there are not other treatable causes of the HC and to ascertain that the bleeding is coming from the bladder and not the kidneys. Bleeding from the kidneys would suggest that the viral infection also involves the kidneys and is not just a superficial infection of the bladder.
        </p>
        <p class="headingAnchor" id="H4032974498">
         <span class="h3">
          Tumor involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HC in patients receiving cancer treatment also includes tumor involvement of the bladder. This could be due to direct tumor invasion from adjacent organs (including the original primary tumor treated with pelvic RT, in those cases), a local recurrence of primary bladder cancer, or a second primary arising in the bladder that may be related to the prior RT [
         <a href="#rid57">
          57
         </a>
         ]. This diagnosis can usually be established with appropriate radiologic imaging, urine cytology, cystoscopy, and cystoscopic bladder biopsy, when indicated based on the initial evaluation.
        </p>
        <p class="headingAnchor" id="H1311752003">
         <span class="h3">
          Urolithiasis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another consideration in the differential diagnosis of gross hematuria is urolithiasis, which typically does not produce clots. (See
         <a class="medical medical_review" href="/z/d/html/7366.html" rel="external">
          "Kidney stones in adults: Diagnosis and acute management of suspected nephrolithiasis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best treatment for hemorrhagic cystitis (HC) is prevention.
        </p>
        <p class="headingAnchor" id="H2388213988">
         <span class="h2">
          Cancer patients receiving ifosfamide and high-dose cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients receiving daily
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         at any dose or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in the setting of hematopoietic cell transplantation (HCT), we recommend forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis and
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         to prevent HC. We suggest against continuous bladder irrigation (CBI) in this setting. (See
         <a class="local">
          'Mesna'
         </a>
         below and
         <a class="local">
          'Forced saline diuresis and continuous bladder irrigation'
         </a>
         below.)
        </p>
        <p>
         Although highly effective, the use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         and forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis does not completely prevent HC in patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . Close monitoring during treatment and careful attention to the earliest symptoms of cystitis are important to prevent progression to more severe HC. Notably, irritative symptoms alone are not a contraindication to continued cyclophosphamide or ifosfamide therapy. (See
         <a class="local">
          'Monitoring for hemorrhagic cystitis during treatment'
         </a>
         below.)
        </p>
        <p>
         Patients receiving high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         should be instructed to drink at least 2 L of fluid a day and to void at first sensation. Oral fluids should be ingested prior to sleep, and patients should awaken once during the night to empty the bladder. Men should be encouraged to stand to void rather than using a bedside urinal in a recumbent position; in our experience, the posterior wall of the bladder is often involved with HC, possibly because use of a bedside urinal at night may be associated with incomplete emptying of the bladder.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Mesna
         </span>
         <span class="headingEndMark">
          —
         </span>
         In keeping with guidelines from the American Society of Clinical Oncology (ASCO), we recommend the use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         to prevent HC in all patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         and in those receiving high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in the setting of HCT [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="local">
          'ASCO guidelines'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          Mesna
         </a>
         is a thiol compound that inactivates acrolein in the urine to reduce the risk of bladder toxicity from oxazaphosphorines such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         . Mesna has been shown to be an effective uroprotective agent in patients receiving these agents, and benefit has been confirmed in randomized trials conducted in cancer patients receiving both ifosfamide and high-dose cyclophosphamide [
         <a href="#rid58">
          58-62
         </a>
         ].
        </p>
        <p>
         Within minutes of intravenous administration,
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         is oxidized to a stable inactive disulfide in the serum, but it is reactivated in the kidney. In the urine, it binds to acrolein, creating an inert thioether that is excreted [
         <a href="#rid63">
          63
         </a>
         ]. The serum half-life of mesna is 90 minutes, while
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         have half-lives of six and seven hours, respectively. As a result, multiple doses are necessary. Mesna
         <strong>
          must
         </strong>
         be present in the bladder at the time of chemotherapy administration in order to be effective.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          Mesna
         </a>
         can be administered intravenously (either continuous or bolus), subcutaneously (continuous) [
         <a href="#rid64">
          64
         </a>
         ], or orally.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous bolus
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         typically uses a dose equal to 60 percent of the total daily dose of
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (at doses &lt;2.5 g/m
         <sup>
          2
         </sup>
         per day) or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , divided into three aliquots and administered prior to and four and eight hours following chemotherapy [
         <a href="#rid65">
          65
         </a>
         ]. However, administration of mesna at 100 percent of the total dose of ifosfamide, divided into two aliquots and administered prior to and four hours following treatment, was as effective and more convenient than three bolus injections of the same dose administered four hours apart [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With continuous infusion regimens of
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         may be administered as a single bolus dose equal to 20 percent of the total ifosfamide dose, followed by continuous infusion of mesna equivalent to 40 percent of the ifosfamide dose, continuing for 12 to 24 hours after ifosfamide completion [
         <a href="#rid21">
          21
         </a>
         ]. Continuous intravenous administration may enhance the nephroprotective effect of mesna with ifosfamide (thought secondary to the metabolite chloroacetaldehyde) while maintaining its uroprotective effect [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral formulations of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         show sustained urinary excretion and urinary bioavailability approaching that of intravenous mesna [
         <a href="#rid68">
          68
         </a>
         ]. The rate and amount of mesna excretion appear to be less variable over time and more prolonged among patients after oral than after intravenous administration [
         <a href="#rid69">
          69-71
         </a>
         ]. The protective effect of combined oral and intravenous mesna appears to be equivalent to that of intravenous mesna alone [
         <a href="#rid69">
          69,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H93784309">
         <span class="h4">
          ASCO guidelines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines are available from an expert panel of ASCO regarding the use, dosing, and schedule of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         in patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         as administered in the setting of HCT; the original 1999 guidelines [
         <a href="#rid22">
          22
         </a>
         ] were upheld and not changed in either the 2002 or the 2009 update [
         <a href="#rid21">
          21,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3335793547">
         <span class="h5">
          Ifosfamide
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous
         </strong>
         <strong>
          mesna
         </strong>
         – The daily dose of intravenous
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         is calculated to equal 60 percent of the total daily dose of
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         , administered as three bolus doses given 15 minutes before and four and eight hours after administration of each ifosfamide dose, when the ifosfamide dose is less than 2.5 g/m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For regimens that employ continuous infusion
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         can be administered as an initial bolus dose equal to 20 percent of the ifosfamide dose, followed by continuous infusion of mesna equal to 40 percent of the ifosfamide dose, continuing for 12 to 24 hours after completion of the ifosfamide infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The panel concluded that there was insufficient evidence on which to base a recommendation for use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         with high-dose
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         (&gt;2.5 g/m
         <sup>
          2
         </sup>
         daily) [
         <a href="#rid21">
          21
         </a>
         ]. However, given the longer half-life of ifosfamide with higher dose therapy, more frequent and prolonged mesna dosing regimens may be needed. We use intravenous mesna at 100 percent of the ifosfamide dose for regimens using ifosfamide doses &gt;2.5 g/m
         <sup>
          2
         </sup>
         per day for three to five days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral
         </strong>
         <strong>
          mesna
         </strong>
         – If the oral route is chosen, oral
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         is not recommended for the initial dose. Patients should receive an initial intravenous bolus injection of mesna equal to 20 percent of the
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         dose at the time of ifosfamide administration, followed by oral mesna tablets at 40 percent of the daily ifosfamide dose, administered at two and six hours following each dose of ifosfamide. Thus, the total daily mesna dose is 100 percent of the ifosfamide dose when the oral route is used. This same dosing schedule is repeated on each day that ifosfamide is administered. If patients vomit within two hours of taking a dose of mesna, they should repeat the dose or receive an intravenous dose of mesna.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3847502653">
         <span class="h5">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the low reported incidence of HC with standard doses of intravenous
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         used for cancer outside of the transplant setting, ASCO does not recommend the routine use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         in these patients; mesna should be used with forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis only in conjunction with high-dose cyclophosphamide administered in the HCT setting (typically 50 mg/kg or 2 g/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. These 1999 recommendations were reiterated in both the 2002 and 2009 updates [
         <a href="#rid21">
          21,23
         </a>
         ]. In this setting, we dose mesna at 80 to 100 percent of the cyclophosphamide dose and administer it over 24 hours.
        </p>
        <p class="headingAnchor" id="H742452315">
         <span class="h3">
          Forced saline diuresis and continuous bladder irrigation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ASCO expert panel on chemotherapy and radiation therapy (RT) protectants recommends that patients receiving high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in the setting of HCT receive
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         in conjunction with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis or saline diuresis alone [
         <a href="#rid22">
          22
         </a>
         ]; this original recommendation from 1999 was upheld in two subsequent guideline updates [
         <a href="#rid21">
          21,23
         </a>
         ]. We typically administer both saline diuresis and mesna in this setting. (See
         <a class="medical medical_review" href="/z/d/html/3538.html" rel="external">
          "Hematopoietic support after hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         In 1991, the use of forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis (hyperhydration) was proposed as a more cost-effective method for uroprotection [
         <a href="#rid73">
          73
         </a>
         ]. The effectiveness of forced saline diuresis (intravenous normal saline at 250 mL/hour and
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         sufficient to maintain urinary output &gt;150 mL/hour) was evaluated in a series of 100 consecutive patients undergoing allogeneic or autologous HCT with a high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         conditioning regimen [
         <a href="#rid74">
          74
         </a>
         ]. In this series, HC developed in 7 percent of patients, and it was clinically significant in only two. The cost was significantly less (USD $20 per course) than the cost of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         (estimated USD $1500 per course).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          Mesna
         </a>
         has been compared with forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis for uroprotection in patients receiving high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         regimens in two separate randomized trials, and the results are mixed [
         <a href="#rid60">
          60,73,75
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial of 100 adult patients undergoing HCT with a cyclophosphamide-containing conditioning regimen failed to find a significant benefit for
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         plus 1.5 L/day of
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         hydration versus 3 L/day of intravenous fluids plus
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         By contrast, in a second prospective randomized trial of 61 consecutive HCT patients,
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         plus 3 L of intravenous hydration daily during high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         was more effective than 6 L of intravenous hydration plus diuresis [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A subsequent trial in 200 patients undergoing HCT with a cyclophosphamide-based conditioning regimen showed that the addition of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         to forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis was more effective than the addition of CBI [
         <a href="#rid60">
          60
         </a>
         ]. Patients randomized to CBI received 200 mL/hour of normal saline, and those randomized to mesna received it by continuous intravenous infusion at 100 percent of the
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         dose. The overall incidence of hematuria of any grade was significantly higher in the CBI group (76 percent) compared with the mesna group (53 percent; p = 0.007). However, the incidence of grade 3 and 4 hematuria was the same in both groups (18 percent). Moderate or severe discomfort or bladder spasms were more frequent in patients receiving CBI than in those receiving mesna (84 versus 2 percent, p &lt;0.0001). Urinary tract infections were also more common in patients receiving CBI (27 versus 14 percent; p = 0.03).
        </p>
        <p class="headingAnchor" id="H756025940">
         <span class="h3">
          Monitoring for hemorrhagic cystitis during treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although highly effective, the use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         and forced
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         diuresis does not completely prevent HC in patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid18">
          18-20,76,77
         </a>
         ]. There are insufficient data to make a recommendation regarding specific monitoring for HC in patients receiving mesna with ifosfamide or cyclophosphamide. In keeping with recommendations from ASCO, during treatment with ifosfamide and high-dose cyclophosphamide, we recommend obtaining a baseline pretreatment urinalysis and monitoring for the development of gross hematuria and for urine output during treatment [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="local">
          'ASCO guidelines'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1531991788">
         <span class="h4">
          Issues related to rechallenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who develop HC during treatment with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , there are no data to inform the safety or advisability of rechallenge with the same drug. If the HC developed in a patient who either did not receive
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         or received suboptimal dosing of mesna, we would attempt retreatment using standard doses of mesna. However, if the HC developed despite the use of mesna, we would probably not rechallenge these individuals.
        </p>
        <p class="headingAnchor" id="H3457965744">
         <span class="h2">
          Non-cancer patients receiving cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no established guidelines for the use of
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         for the prevention of bladder toxicity secondary to
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for treatment of rheumatic diseases, and practice patterns vary among clinicians. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Prevention of drug-induced cystitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1760164724">
         <span class="h2">
          Patients receiving pelvic radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific recommendation can be made for prevention of late radiation cystitis in patients undergoing pelvic RT.
        </p>
        <p class="headingAnchor" id="H4006602535">
         <span class="h3">
          Amifostine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          Amifostine
         </a>
         is an aminothiol that is cytoprotective in several tissues, including hematopoietic progenitor cells, renal cells, myocardium, intestinal epithelium, neuronal cells, and bladder urothelium [
         <a href="#rid78">
          78-81
         </a>
         ]. The proposed mechanism of action involves the production of an active thiol metabolite, which acts as an intracellular scavenger of free radicals.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          Amifostine
         </a>
         has shown potential value for the prevention of both gastrointestinal and acute bladder toxicity from radiation. As an example, in one randomized trial, 205 patients undergoing RT for advanced pelvic malignancies were randomly assigned to daily intravenous amifostine (340 mg/m
         <sup>
          2
         </sup>
         over three to five minutes daily, 15 to 30 minutes before RT) or no amifostine [
         <a href="#rid82">
          82
         </a>
         ]. The rate of grade &gt;2 acute bladder toxicity was significantly less in the amifostine group by week 4 (14 versus 5 percent), and this difference was even more pronounced at week 7 (33 versus 0 percent).
        </p>
        <p>
         However, there are no data supporting the ability of
         <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">
          amifostine
         </a>
         to prevent late bladder toxicity, including HC. Despite the data from this trial, amifostine is not used clinically in modern RT treatment plans.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2971542204">
         <span class="h2">
          General approach to intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         If hematuria develops despite the use of preventive measures (in patients treated with
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) or following pelvic radiation therapy (RT), numerous treatment options are available depending on the severity of hemorrhagic cystitis (HC). A management algorithm outlining our approach is provided  (
         <a class="graphic graphic_algorithm graphicRef132361" href="/z/d/graphic/132361.html" rel="external">
          algorithm 1
         </a>
         ), and discussed in detail in the following sections.
        </p>
        <p>
         An important point is that for patients who are actively bleeding, platelet counts should be maintained at &gt;50,000/microL, and potentially correctable bleeding disorders (including use of medications such as anticoagulants or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         that might be associated with an increased risk of bleeding) should be addressed.
        </p>
        <p>
         While there is no consensus on the optimal management of this condition, typically a stepwise approach to treatment is used, balancing the risks/benefits of each modality and the severity of the condition. Interventions for HC are similar regardless of the underlying etiology (chemotherapy versus RT). In general:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Common Terminology Criteria for Adverse Events [CTCAE] grade 1  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ) – Mild HC with irritative lower urinary tract symptoms and without clots following
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         treatment is generally transient and does not necessitate transfusion or clot extraction/irrigation. Treatment generally requires only outpatient management with hydration, with or without anticholinergic bladder medications for management of bladder spasms. If the hematuria clears and a repeat urinalysis four to six weeks after the inciting event does not show persistent hematuria, we would not pursue further diagnostic workup. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent or more severe (CTCAE grade 2 to 3  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         )) HC – Persistent mild or moderate HC, with or without clots, necessitates more invasive initial management, such as continuous bladder irrigation (CBI) with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , or cystoscopy under anesthesia, to extract clots and to identify and fulgurate bleeding sources (if identified). Successful treatment may also require instillation of astringents such as
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         ,
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         , or
         <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">
          silver nitrate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HBO may be useful, especially for patients with radiation-induced HC, but it is limited to relatively stable patients with access to a hyperbaric chamber. Another potential option for radiation cystitis is antioxidant therapy with vitamins E and C. Although there are no published reports specific to radiation-induced HC, there are data on benefit in chronic radiation proctitis [
         <a href="#rid83">
          83
         </a>
         ], a late toxicity for which the cause is the same. (See
         <a class="local">
          'Radiation therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7058.html" rel="external">
          "Radiation proctitis: Clinical manifestations, diagnosis, and management", section on 'Other therapies with an unclear role'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CTCAE grade 3 to 4  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ) – Severe HC requires transfusions, and in addition to cystoscopy under anesthesia (to extract clots and to identify and fulgurate bleeding sources) and intravesical agent instillation as above, it may require more intensive interventions, such as intravesical formalin instillation, iliac artery angioembolization, temporary or permanent urinary diversion, and/or cystectomy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3423750154">
         <span class="h2">
          Initial management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management of HC varies based on condition severity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with mild HC (ie, grade 1  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ), including those with gross hematuria without clots, adequate bladder emptying (as assessed by postvoid residual), and lower urinary tract symptoms, conservative measures, including hydration and anticholinergic bladder medications (as needed for bladder spasms), may be used in an outpatient setting after urinalysis and urine culture to exclude infection [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients presenting with the passage of blood clots (moderate or severe HC), initial management includes assessment of hemodynamic stability, hydration (or transfusion if needed), and ensuring adequate bladder drainage. Typically, in these scenarios, patients are admitted to the hospital for observation and interventions. (See
         <a class="local">
          'Tempo and location of the evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A large-bore (≥22 Fr) three-way Foley catheter is placed to allow for manual clot irrigation with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">
          "Placement and management of urinary bladder catheters in adults", section on 'Specialized catheters'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the urine clears following manual irrigation, subsequent conservative management with hydration alone may be sufficient. If the hematuria or clots persist despite manual catheter irrigation, CBI with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         may be initiated. Ensuring adequate fluid outflow from the three-way catheter while on CBI is important because if the outflow channel becomes blocked, the bladder will continue to distend with the fluid being instilled, which risks perforation. Notably, outflow obstruction can present as worsening abdominal pain or persistent bladder spasms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the three-way catheter has repeated obstruction, the clots cannot be removed by hand irrigation, or the patient does not improve with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         CBI, the next step is cystoscopy under anesthesia. While there are no data on the time to resolution with saline CBI alone, without repeated obstruction, we typically utilize this strategy for two to four days if the above conditions are not met and the patient's hemodynamic parameters allow. Proceeding with cystoscopy under anesthesia allows for clot evacuation  (
         <a class="graphic graphic_picture graphicRef117631" href="/z/d/graphic/117631.html" rel="external">
          picture 1
         </a>
         ), fulguration of bleeding vessels (if they are identified), and management of any bladder tumors (if present). Notably, given the typical diffuse mucosal bleeding in HC, identifying a discrete bleeding vessel is not common. In one report of 33 patients with HC associated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or RT, 14 (42 percent) had resolution of hematuria after a single cystoscopy under anesthesia including clot evacuation or fulguration [
         <a href="#rid85">
          85
         </a>
         ]. Only 4 of 11 patients who initially did not respond had resolution after a total of two or more cystoscopies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Traditionally, cystoscopic bladder fulguration has been accomplished with electrocautery; however, some small case series note successful use of lasers for coagulation [
         <a href="#rid86">
          86,87
         </a>
         ]. In these studies, a GreenLight potassium titanyl phosphate (KTP) laser (530 nm wavelength) and a 980 nm diode laser were used to manage radiation-induced HC. In an additional study, a GreenLight Xcelerated Performance System (XPS) laser (1064 nm wavelength) was successfully used in four patients who had previously failed fulguration with electrocautery [
         <a href="#rid88">
          88
         </a>
         ]. The GreenLight XPS laser was also used in a series of 12 patients requiring blood transfusion from radiation-induced HC. Of these, nine were successfully treated, two had improvement but required a repeat procedure, and one proceeded to more aggressive therapy [
         <a href="#rid89">
          89
         </a>
         ]. Notably, attention must be paid to the depth of laser penetration and the risk of bladder and intestinal perforation; in at least one case, fatal intestinal perforation was reported following laser coagulation for radiation cystitis in a female patient [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1360397842">
         <span class="h2">
          Interventions for persistent or moderate hematuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         If despite the above measures, the patient has persistent gross hematuria, with or without clots, additional interventions, such as intravesical instillations and HBO, may be utilized. Notably, most of the data regarding intravesical agent instillation consist of retrospective case series. There is no consensus on the best way to manage those with persistent or severe gross hematuria despite these initial measures. In general, it is best to start with the least aggressive intervention that is least likely to exacerbate the HC and then progress to more aggressive measures only when necessary.
        </p>
        <p class="headingAnchor" id="H1120038983">
         <span class="h3">
          Alum
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the efficacy and tolerable side effect profile of intravesical
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         instillation, it is commonly the first intravesical therapy utilized when other more conservative measures have failed.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          Alum
         </a>
         (aluminum ammonium sulfate or aluminum potassium sulfate) is an astringent that induces hemostasis by precipitating protein over the bleeding surface. Since it has low cell permeability, its action is limited to the cell surface and interstitial spaces. Prior to intravesical alum instillation, it is important to ensure that all clot has been removed from the bladder, as clot removal after alum instillation can be challenging. Alum administration is typically performed with a 1 percent solution (50 g of alum dissolved in 5 L of sterile water) that is used to continuously irrigate the bladder via a three-way Foley catheter (250 to 300 cc/hour) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         The success of this approach can be illustrated by a retrospective report in which continuous intravesical irrigation with a 1 percent
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         solution was administered to 60 patients with HC [
         <a href="#rid91">
          91
         </a>
         ]. Bleeding was controlled in 60 percent, with the most common adverse event being bladder spasms. At a median follow-up of 17 months, 33 percent of the cohort needed no other treatments for HC.
        </p>
        <p>
         Severe side effects after intravesical
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         instillation are uncommon, most side effects resulting in local irritative voiding symptoms [
         <a href="#rid92">
          92
         </a>
         ]. Toxicity from systemic absorption is less common; however, there are six reported cases in the literature of acute aluminum toxicity in patients with chronic kidney disease who received intravesical alum irrigation for HC [
         <a href="#rid93">
          93-96
         </a>
         ]. Clinically, aluminum toxicity may present with mental status changes, malaise, speech changes, and seizures [
         <a href="#rid94">
          94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1839.html" rel="external">
          "Aluminum toxicity in chronic kidney disease"
         </a>
         .)
        </p>
        <p>
         If aluminum toxicity is suspected, serum aluminum levels can be monitored; toxicity is reported at a mean level of 7.4 micromol/L [
         <a href="#rid97">
          97
         </a>
         ]. Of note, in a study of 12 patients with normal renal function undergoing intravesical
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         therapy, the mean serum aluminum level rose from 1.68 micromol/L at baseline to 3.36 micromol/L, without any episodes of clinical toxicity [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3235415576">
         <span class="h3">
          Aminocaproic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          Aminocaproic acid
         </a>
         is a synthetic lysine that decreases fibrinolysis by competitively inhibiting plasminogen and plasmin [
         <a href="#rid99">
          99
         </a>
         ]. It can be given either as an intravesical instillation or orally, as the majority of the orally administered drug is secreted unchanged in the urine [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         For patients with HC,
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         is administered intravesically as 200 mg of aminocaproic acid per 1 L of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , or orally in divided doses of 100 to 150 mg/kg per day. In several small case series, the reported success rates for use of aminocaproic acid by either route for HC are between 92 and 100 percent [
         <a href="#rid101">
          101-103
         </a>
         ]. Potential adverse side effects include thrombotic complications, rhabdomyolysis, and myopathy. Importantly, if considered for oral administration, upper urinary tract bleeding must be ruled out (potentially via computed tomography [CT] urogram) before administration, as ureteral obstruction from upper tract clots has been reported.
        </p>
        <p class="headingAnchor" id="H2305265740">
         <span class="h3">
          Silver nitrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">
          Silver nitrate
         </a>
         can be used for intravesical instillation; it is proposed that when instilled, the compound is converted into nitric acid, which causes chemical cauterization of the urothelium. Notably, the preparation must be made using sterile water rather than
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , as silver nitrate mixed with saline causes precipitation. Solution concentrations of 0.01 to 1 percent can be used; however, instillation under anesthesia is needed for concentrations ≥0.5 percent [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         While largely discussed and referred to as an option for treatment, clinical data regarding the efficacy of
         <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">
          silver nitrate
         </a>
         in this setting are sparse. In our own experience, there has been limited success with this treatment modality [
         <a href="#rid104">
          104
         </a>
         ]. As there is the potential for obstruction from precipitation after instillation, a cystogram should be performed to rule out ureteral reflux prior to intravesical instillation [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2057049329">
         <span class="h3">
          Hyperbaric oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Where available, HBO may be useful, especially for patients with radiation-induced HC. However, HBO is limited to relatively stable patients who have access to a hyperbaric chamber.
        </p>
        <p>
         The rationale for use of HBO is that it may promote healing by increasing tissue oxygenation and aid in angiogenesis [
         <a href="#rid106">
          106,107
         </a>
         ]. HBO appears to be effective for both RT-induced and chemotherapy-induced HC, although the bulk of the efficacy data are in patients with radiation-induced HC. The clinical response rate (partial or complete resolution) in this setting in a pooled analysis of 602 patients with at least 12 months of follow-up was 84 percent (95% CI 76-91) [
         <a href="#rid108">
          108-117
         </a>
         ]. The following data are available:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of HBO was initially described in patients with radiation-induced HC [
         <a href="#rid109">
          109
         </a>
         ]. Most of these patients had severe inflammation requiring blood transfusion, but they were hemodynamically stable enough to be confined to a hyperbaric chamber under the supervision of a registered nurse and without the direct presence of a clinician. All but one patient had failed prior therapy. The oxygen tension was raised slowly to 2 atm. Each session was two hours, and 60 sessions were planned, with a cystoscopic examination after 30 treatments. Twelve of 13 patients experienced durable cessation of HC. The single failure demonstrated full-thickness bladder necrosis at the time of bladder removal (cystectomy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar favorable results were reported in several more contemporary series, in which complete resolution or marked improvement in symptoms of HC was seen in 65 to 81 percent of patients, respectively, with a regimen of 100 percent oxygen at 2 to 2.5 atm for 90 to 120 minutes during 20 to 40 sessions [
         <a href="#rid110">
          110-115,118
         </a>
         ]. In three of the studies, outcomes appeared better when patients were treated earlier in the disease course (ie, within six months of hematuria onset). Cystoscopies done at resolution of HC demonstrated resolution of the underlying pathology and return to normal bladder mucosa and function [
         <a href="#rid110">
          110,111,118
         </a>
         ]. The most common reported side effect of HBO has been otalgia, which in one report, was seen in 33 percent of patients and resolved after placement of tympanostomy tubes [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are only two randomized trials of HBO for HC:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HBO (100 percent oxygen at 2.5 atm for 60 minutes daily, seven days per week for 30 days) was compared with intravesical hyaluronic acid instillation (40 mg of hyaluronic acid instilled in the bladder by Foley catheter for at least 20 minutes weekly for one month and then monthly for the following two months) in one small randomized trial of 36 patients with radiation-induced HC [
         <a href="#rid119">
          119
         </a>
         ]. There were no significant differences between the treatments at 12 months in terms of efficacy (complete response in 10 of 20 patients treated with HBO compared with 12 of 16 in the hyaluronic acid group; partial response in 7 of 20 versus 3 of 16, respectively). No adverse complications were seen in either group, other than an increase in urinary tract infections in the hyaluronic acid group (thought to be secondary to repeated catheterizations).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         On the other hand, benefit for HBO was shown in the RICH-ART (Radiation Induced Cystitis treated with Hyperbaric oxygen—A Randomised controlled Trial) trial, in which 87 individuals who had completed pelvic RT at least six months previously, who scored &lt;80 in the urinary domain of the Expanded Prostate Index Composite (EPIC) score [
         <a href="#rid120">
          120
         </a>
         ], and who had been referred to one of five participating Nordic HBO clinics due to symptoms of late radiation cystitis were randomly assigned to "standard care" only or standard care plus HBO (30 to 40 sessions of 100 percent oxygen breathed at a pressure of 240 to 250 kilopascals [kPa], equivalent to 2.36 to 2.46 atm) for 80 to 90 minutes daily [
         <a href="#rid116">
          116
         </a>
         ]. Exclusion criteria included ongoing transfusion-dependent bleeding, permanent urinary catheter, bladder capacity &lt;100 mL, fistula in the urinary bladder, prior HBO for late radiation injuries, and contraindication to HBO. Specific treatment in the control group was neither prescribed nor described, but it included the option of undergoing HBO after the fourth and final study visit, which took place approximately six to eight months postrandomization. Notably, eight patients withdrew consent after randomization (seven who were assigned to the control group), and the intent-to-treat analysis included 79 patients. The primary endpoint was patient-perceived urinary symptoms, assessed with EPIC from randomization to the final study visit. The difference between change in group mean EPIC score was 10.1 points (95% CI 2.2-18.1, p = 0.013, 17.8 points in the HBO group and 7.7 points with standard care). Previous studies of the EPIC urinary total score had shown that the minimal clinically important difference was 9 points or less [
         <a href="#rid120">
          120,121
         </a>
         ]. When categorized according to this minimal clinically important difference, in the HBO group, 73 percent of patients improved by the fourth visit, 23 percent had no change, and 5 percent worsened. In the standard care group, 34 percent improved, 54 percent had no change, and 11 percent worsened. Long-term outcomes were not described.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Adverse events affected 17 of the 41 patients in the HBO group (41 percent). Six had temporary ear pain during pressurization of the hyperbaric chamber, and four had signs of barotrauma (with paracentesis of the tympanic membrane needed in one). Hyperoxia-induced transient myopia with visual changes was reported in five (12 percent). These events were felt to be clearly related to HBO. The relationship of other adverse effects to HBO (infection, transient muscle cramps or pain, hematuria, diarrhea, fatigue, nausea, headache) was uncertain.
        </p>
        <p>
        </p>
        <p>
         Although initial control rates are high, there is a risk of hematuria recurrence, which in one series, was 73 percent at five years after treatment [
         <a href="#rid122">
          122
         </a>
         ]. Limited data from case reports also support benefit for HBO in patients with cyclophosphamide-induced HC [
         <a href="#rid123">
          123,124
         </a>
         ].
        </p>
        <p>
         In the United States,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fconsumer-updates%2Fhyperbaric-oxygen-therapy-get-facts%3Futm_medium%3Demail%26utm_source%3DgovdeliveryA&amp;token=tjZFG%2BUegXo2j1%2BNea%2B2Ia8k%2B9U3FlogQcnPHVlZGe1tIV8dt6O0cWYJn5ROQLCAlOHRxOe9CzPz6qLwz3U9NE3OZ%2FxxXn19lm%2FgwMI%2BHi22nWvl39PSs3S1zlmhmPyqgXxkxJM4cz%2FixTUhRyEJXg%3D%3D&amp;TOPIC_ID=2829" target="_blank">
          HBO therapy is cleared for use by the US Food and Drug Administration (FDA)
         </a>
         in patients with radiation-related injury (including cystitis) but not for chemotherapy-related HC.
        </p>
        <p class="headingAnchor" id="H1270898932">
         <span class="h3">
          Other interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other less commonly used interventions for persistent or moderate HC are oral
         <a class="drug drug_general" data-topicid="9755" href="/z/d/drug information/9755.html" rel="external">
          pentosan polysulfate
         </a>
         sodium (PPS), conjugated estrogens, recombinant factor VIIa, and antioxidants. Most of the data suggesting benefit from any of these therapies come from small series and case reports, and optimal patient selection for any of these treatments is not established.
        </p>
        <p class="headingAnchor" id="H1996530738">
         <span class="h4">
          Pentosan polysulfate sodium
         </span>
         <span class="headingEndMark">
          —
         </span>
         PPS is a low molecular weight heparin (LMWH)-like compound with anticoagulant and fibrinolytic effects that has been approved for symptomatic treatment of interstitial cystitis. Its proposed mechanism of action is reconstitution of the deficient protective glycosaminoglycan layer over the urothelium. Of note, pigmentary retinopathy has been reported with
         <a class="drug drug_general" data-topicid="9755" href="/z/d/drug information/9755.html" rel="external">
          pentosan polysulfate
         </a>
         use. Typically this occurred after three years of use or longer, although cases have been seen with shorter use. Patients treated with PPS should be undergo close ophthalmologic evaluation, including periodic retinal examinations. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8087.html" rel="external">
          "Interstitial cystitis/bladder pain syndrome: Management", section on 'Pentosan polysulfate sodium as alternative'
         </a>
         .)
        </p>
        <p>
         In multiple series, oral PPS has been effective in controlling hematuria in both RT-induced and cyclophosphamide-induced HC [
         <a href="#rid125">
          125-127
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 14 patients with HC following RT, treatment with PPS resulted in complete control of hematuria in 10 patients, while three had partial control [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another report, oral PPS (100 mg three times a day) was used as the primary management for 60 patients with HC associated with pelvic RT or systemic chemotherapy [
         <a href="#rid126">
          126
         </a>
         ]. In 31 of 51 evaluable patients, PPS was eventually discontinued or the dose was reduced without recurrence of hematuria.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H959375742">
         <span class="h4">
          Conjugated estrogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of systemic estrogen therapy for treatment of HC is uncertain given the disparate data regarding benefit and the potential for adverse events, including hormone-dependent cancers and venous thromboembolism.
        </p>
        <p>
         Several older, uncontrolled, small reports suggested that oral conjugated estrogens are a simple and effective treatment option for mild HC [
         <a href="#rid128">
          128-131
         </a>
         ]; however, a more recent randomized study of conjugated estrogen (6.25 mg daily) for chemotherapy-induced HC following hematopoietic cell transplantation (HCT) in 56 patients did not demonstrate a benefit over the control group [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H382147132">
         <span class="h4">
          Recombinant factor VIIa
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of intravenous recombinant factor VIIa is unclear. The available data are mixed, and any benefit appears to be transient.
        </p>
        <p>
         A few case reports note benefit from intravenous infusion of activated recombinant factor VII (NovoSeven) in patients with refractory HC [
         <a href="#rid133">
          133-137
         </a>
         ]. Notably, in three of these studies, the treatment response was transient, with all patients returning to their baseline level of HC within 24 hours [
         <a href="#rid134">
          134,136,137
         </a>
         ]. Furthermore, in a randomized trial of 26 patients with mild or moderate HC, there was no aggregate benefit of recombinant factor VIIa in the management of bleeding complications following HCT. Specifically, having the bladder as the primary site of bleeding was significantly associated with a negative impact on the bleeding outcome [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3662938029">
         <span class="h4">
          Antioxidants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another potential option for radiation cystitis is antioxidant therapy with vitamins E and C. Although there are no published reports specific to radiation-induced HC, there are data describing benefit in chronic radiation proctitis [
         <a href="#rid83">
          83
         </a>
         ], a late radiation-related toxicity for which the cause is the same. (See
         <a class="local">
          'Radiation therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7058.html" rel="external">
          "Radiation proctitis: Clinical manifestations, diagnosis, and management", section on 'Other therapies with an unclear role'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4269859115">
         <span class="h2">
          Severe and/or refractory hemorrhagic cystitis
         </span>
        </p>
        <p class="headingAnchor" id="H4005835378">
         <span class="h3">
          Urinary diversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary diversion can be performed in a temporary or permanent nature with percutaneous nephrostomy tube placement. Typically, this is used in stable patients who have failed more conservative measures. In small case series, urinary diversion in this fashion has demonstrated success in the management of HC [
         <a href="#rid138">
          138,139
         </a>
         ]. Given the limited morbidity of nephrostomy tube placement, it could be considered in conjunction with or following intravesical therapies.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Formalin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the inherent toxicity and the potential for long-term bladder dysfunction, formalin is typically reserved for severe cases of HC following failure of other intravesical therapies.
        </p>
        <p>
         Formalin is a 37 percent aqueous solution of formaldehyde. Formalin acts by hydrolyzing proteins and coagulating the tissue on a superficial level, controlling hemorrhage in the mucosa and submucosa. Intravesical instillation of dilute formalin has been used for many years in the treatment of intractable HC [
         <a href="#rid140">
          140-143
         </a>
         ]. Instillations typically start with a 1 percent formalin instillation under general or regional anesthesia, and if the treatment is not successful, the dose is later escalated. Instillations are typically performed following a cystogram (to ensure there is no bladder perforation or ureteral reflux), under low pressure (&lt;15 cm H
         <sub>
          2
         </sub>
         O), and with a short dwell time (10 to 15 minutes) [
         <a href="#rid144">
          144-146
         </a>
         ]. Formalin is caustic, so in addition to the longer term risk of bladder dysfunction, there is a risk of ureteral stricture and injury to the genital skin and perineum if they are not adequately protected. With instillation, the catheter should be kept on slight tension to occlude the bladder neck and prevent urethral exposure. If ureteral reflux is present, the ureters can be obstructed with occlusive catheters prior to formalin instillation.
        </p>
        <p>
         While acknowledging the increased risk with intravesical formalin instillation, there is evidence supporting efficacy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an early study, 35 patients treated with RT for cervical cancer who developed HC and failed conservative therapy with hydration, bladder irrigation, and clot extraction underwent treatment with diluted formalin (1, 2, and 4 percent in 22, 10, and 4 patients, respectively) by passive irrigation for 20 to 30 minutes, followed by continuous
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         irrigation for 24 to 48 hours [
         <a href="#rid142">
          142
         </a>
         ]. Thirty-one (89 percent) had a complete response to a single instillation, but HC recurred in seven after a median of seven months. One percent formalin was as effective as 2 or 4 percent formalin. Minor complications occurred in 19 patients and included mild fever, frequency, dysuria, suprapubic pain, transient incontinence, unilateral hydronephrosis, ureterovesical reflux, and decreased bladder capacity not requiring diversion. Major complications occurred in 11 patients (31 percent) and included bilateral ureteral stenosis causing hydronephrosis, vesicovaginal fistula, decreased bladder capacity requiring diversion, and one death due to bleeding and formalin toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A more contemporary series included eight patients with radiation-induced HC refractory to bladder irrigation, clot extraction, and other intravesical agents who were managed with intravesical formalin [
         <a href="#rid144">
          144
         </a>
         ]. The concentration ranged from 1 to 4 percent, with escalation of dose used for treatment failures. Five patients received a single dose, two received two doses, and one received three doses. At a median follow-up of eight months, six had resolution of hematuria (75 percent), with a median time to resolution of four days. Two of these eventually required cystectomy, one because of recurrent hematuria and the other for bladder neck contracture and bladder dysfunction.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          Vascular interventions and extirpative surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with persistent severe HC despite the previous measures, or in those with life-threatening bleeding, iliac artery angioembolization and bladder removal (cystectomy) are "last resort" options.
        </p>
        <p class="headingAnchor" id="H2966306477">
         <span class="h4">
          Selective iliac artery embolization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective iliac artery embolization has been successfully utilized in cases of refractory HC or in acutely unstable patients, with resolution of bleeding in up to 92 percent of cases [
         <a href="#rid147">
          147-149
         </a>
         ]. This is typically performed with placement of an occlusive material (eg, gel foam, coils, etc) in the anterior division of the internal iliac artery. This is occluded as its further branches provide blood supply to the bladder via the vesical arteries. Otherwise, selective embolization of the vesical arteries may be possible. In both cases, embolization is performed after the posterior division has branched off the internal iliac artery to avoid occluding the superior gluteal artery, which would result in gluteal pain [
         <a href="#rid150">
          150
         </a>
         ]. Other rare severe complications, including bladder necrosis, and embolization of the occlusive material to distal arterial branches have been reported [
         <a href="#rid151">
          151
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H454988207">
         <span class="h4">
          Cystectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, surgical removal of the bladder is needed to control hemorrhage. In the largest available series on cystectomy and surgical urinary diversion for HC, RT was the underlying etiology in 81 percent of cases [
         <a href="#rid152">
          152
         </a>
         ].
        </p>
        <p>
         Typically, this is accomplished with a simple cystectomy and ileal or transverse colon conduit formation (depending on what bowel segment is healthy in those with prior pelvic RT) [
         <a href="#rid152">
          152-154
         </a>
         ]. Of all the treatments mentioned, cystectomy is a treatment of last resort, as it is associated with a high risk of perioperative complications and mortality [
         <a href="#rid152">
          152
         </a>
         ]. In patients too ill for urinary diversion with an intestinal segment, the ureters can be ligated, and the patient can be managed with percutaneous nephrostomy tubes or cutaneous ureterostomy following cystectomy.
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – Hemorrhagic cystitis (HC) is a sterile cystitis with hematuria. It most often occurs in patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         in preparation for hematopoietic cell transplantation (HCT), and is a late complication in 6 to 9 percent of patients receiving pelvic radiation therapy (RT). (See
         <a class="local">
          'Incidence and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation and diagnosis
         </strong>
         – Clinical presentation ranges from mild hematuria and bladder irritation, to gross hematuria with clots and life-threatening persistent hemorrhage. Severity is graded based on the degree of hematuria and the intensity of therapy required  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A clinical diagnosis of HC is made in patients with hematuria and lower urinary tract symptoms, after excluding other potential causes; biopsy is not required. Workup includes urinalysis and urine culture; selected patients may require cystoscopy, urine cytology, and upper urinary tract imaging. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of prevention and monitoring
         </strong>
         – All patients receiving
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         or high-dose
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         require hyperhydration (intravenous normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         at 250 mL/hour and
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         sufficient to maintain urinary output &gt;150 mL/hour). In addition, we recommend
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         in all patients receiving ifosfamide or high-dose cyclophosphamide in the setting of HCT (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Mesna'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For most patients, we perform a pretreatment urinalysis and monitor urine output for the development of gross hematuria. (See
         <a class="local">
          'Monitoring for hemorrhagic cystitis during treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment depends on severity and does not differ by underlying etiology (chemotherapy versus RT). There is no consensus on the optimal management (see
         <a class="local">
          'General approach to intervention'
         </a>
         above). We use a stepwise approach that balances the risks/benefits of each modality and HC severity, which is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef132361" href="/z/d/graphic/132361.html" rel="external">
          algorithm 1
         </a>
         ) and summarized below:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild
         </strong>
         – For patients with mild HC, we suggest conservative management (hydration and anticholinergic bladder medications for painful bladder spasms) rather than more aggressive interventions while performing initial diagnostic studies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) to exclude other etiologies. This is often performed in the outpatient setting. Mild HC includes grade 1 HC  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ), and HC with gross hematuria without clots, adequate bladder emptying (as assessed by postvoid residual), and only lower urinary tract symptoms. (See
         <a class="local">
          'Initial management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We repeat the urinalysis four to six weeks after the inciting cause to document resolution, with referral/additional workup if hematuria persists.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate or severe or blood clots
         </strong>
         – For patients passing blood clots or with moderate or severe HC  (
         <a class="graphic graphic_table graphicRef91254" href="/z/d/graphic/91254.html" rel="external">
          table 2
         </a>
         ), we first assess hemodynamic stability, maximize hydration (or transfusion if needed), and ensure adequate bladder drainage. Most patients are admitted to the hospital. Once the patient is stabilized and adequate bladder drainage is secured, we proceed with cystoscopy, urine cytology, and upper urinary tract imaging to identify contributing etiologies. (See
         <a class="local">
          'Tempo and location of the evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with blood clots, we place a large-bore (≥22 Fr) three-way Foley catheter to allow for manual clot irrigation with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">
          "Placement and management of urinary bladder catheters in adults", section on 'Specialized catheters'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the urine clears following manual irrigation, we offer a trial of conservative management with hydration alone. If gross hematuria or clots persist despite manual catheter irrigation, we initiate continuous bladder irrigation (CBI) with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If the three-way catheter has repeated obstruction, the clots cannot be removed by hand irrigation, or the patient does not improve with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         CBI, the next step is cystoscopy under anesthesia. For those without indications for cystoscopy, we typically continue saline CBI for two to four days as long as the patient's hemodynamic parameters allow.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Persistent/refractory symptoms
         </strong>
         – If despite the above measures, the patient has persistent gross hematuria, with or without clots, therapy is individualized and prioritizes less invasive/toxic options when feasible. Options include (see
         <a class="local">
          'Interventions for persistent or moderate hematuria'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intravesical instillations of
         <a class="drug drug_general" data-topicid="141418" href="/z/d/drug information/141418.html" rel="external">
          alum
         </a>
         ,
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         , or
         <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">
          silver nitrate
         </a>
         . Intravesicular instillation of formalin is more toxic and reserved for severe and/or refractory HC.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hyperbaric oxygen, especially for relatively stable patients with radiation-induced HC. (See
         <a class="local">
          'Hyperbaric oxygen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Antioxidant therapy with vitamins E and C. (See
         <a class="local">
          'Antioxidants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Temporary or permanent urinary diversion with percutaneous nephrostomy tube placement. (See
         <a class="local">
          'Severe and/or refractory hemorrhagic cystitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Iliac artery angioembolization and cystectomy are "last resort" options reserved for those with life-threatening bleeding and/or persistent severe HC refractory to other measures. (See
         <a class="local">
          'Vascular interventions and extirpative surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1365183771">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Beverly Moy, MD, MPH, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ilhan O, Koç H, Akan H, et al. Hemorrhagic cystitis as a complication of bone marrow transplantation. J Chemother 1997; 9:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efros MD, Ahmed T, Coombe N, Choudhury MS. Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology 1994; 43:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer 1981; 17:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li KD, Jones CP, Hakam N, et al. Haemorrhagic cystitis: a review of management strategies and emerging treatments. BJU Int 2023; 132:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PHILIPS FS, STERNBERG SS, CRONIN AP, VIDAL PM. Cyclophosphamide and urinary bladder toxicity. Cancer Res 1961; 21:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox PJ. Cyclophosphamide cystitis and bladder cancer. A hypothesis. Eur J Cancer 1979; 15:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korkmaz A, Oter S, Deveci S, et al. Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats. J Urol 2003; 170:2498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souza-Fiho MV, Lima MV, Pompeu MM, et al. Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Am J Pathol 1997; 150:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korkmaz A, Oter S, Sadir S, et al. Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats. J Urol 2005; 173:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 2007; 23:303.
          </a>
         </li>
         <li class="breakAll">
          Williams JA, Clarke D. Pelvic radiation necrosis and radiation cystitis. In: Hyperbaric Medicine Practice, Kindwall EP (Ed), Best Publishing, Arizona 1994. p.505.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovach JS, Schutt AJ, Hahn RG, et al. A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer. Oncology 1974; 29:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bremner DN, McCormick JS, Thomson JW. Clinical trial of isophosphamide (NSC-109724)--results and side effects. Cancer Chemother Rep 1974; 58:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res 1972; 32:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988; 80:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teufel G, Pfleiderer A. [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)]. Geburtshilfe Frauenheilkd 1976; 36:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creaven PJ, Allen LM, Cohen MH, Nelson RL. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep 1976; 60:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemeny N, Reichman B, Dougherty J, et al. Phase II trial of ifosfamide and mesna in advanced colorectal cancer. Cancer Treat Rep 1987; 71:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheulen ME, Niederle N, Bremer K, et al. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev 1983; 10 Suppl A:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nobile MT, Rosso R, Brema F, et al. Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors. Tumori 1984; 70:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20:2895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold H, Bourseaux F, Brock N. Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester. Naturwissen-Schaften 1958; 45:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brade WP, Herdrich K, Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong TM, Yeo W, Chan LW, Mok TS. Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. Gynecol Oncol 2000; 76:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall A, McGrath C, Torigian D, et al. Low-dose cyclophosphamide associated with hemorrhagic cystitis in a breast cancer patient. Breast J 2012; 18:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uppugunduri CRS, Storelli F, Mlakar V, et al. The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Front Pharmacol 2017; 8:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant 2015; 50:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence HJ, Simone J, Aur RJ. Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 1975; 36:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice SJ, Bishop JA, Apperley J, Gardner SD. BK virus as cause of haemorrhagic cystitis after bone marrow transplantation. Lancet 1985; 2:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyamura K, Takeyama K, Kojima S, et al. Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakazawa Y, Saito S, Yanagisawa R, et al. Recipient seropositivity for adenovirus type 11 (AdV11) is a highly predictive factor for the development of AdV11-induced hemorrhagic cystitis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2013; 48:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011; 31:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedi A, Miller CB, Hanson JL, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arthur RR, Shah KV, Baust SJ, et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986; 315:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendenhall WM, Henderson RH, Costa JA, et al. Hemorrhagic radiation cystitis. Am J Clin Oncol 2015; 38:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol 2010; 7:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levenback C, Eifel PJ, Burke TW, et al. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol 1994; 55:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inokuchi H, Mizowaki T, Norihisa Y, et al. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol 2017; 6:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 2013; 87:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harsolia A, Vargas C, Yan D, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys 2007; 69:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011; 117:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005; 61:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo P. Urologic emergencies in the cancer patient. Semin Oncol 2000; 27:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002; :CD001773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol 1990; 143:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liem X, Saad F, Delouya G. A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis. Drugs 2015; 75:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson NA, Notley RG. Urological complications of cyclophosphamide. Br J Urol 1973; 45:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pode D, Perlberg S, Steiner D. Busulfan-induced hemorrhagic cystitis. J Urol 1983; 130:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millard RJ. Busulfan-induced hemorrhagic cystitis. Urology 1981; 18:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol 2020; 204:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traystman MD, Gupta PK, Shah KV, et al. Identification of viruses in the urine of renal transplant recipients by cytomorphology. Acta Cytol 1980; 24:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol 1980; 74:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016; 352:i851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakurai M, Saijo N, Shinkai T, et al. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial. Jpn J Clin Oncol 1986; 16:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuoka M, Negoro S, Masuda N, et al. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991; 117:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vose JM, Reed EC, Pippert GC, et al. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993; 11:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant BM, Jarman M, Ford HT, Smith IE. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980; 2:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 1979; 63:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev 1983; 10 Suppl A:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markman M, Kennedy A, Webster K, et al. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Semin Oncol 1996; 23:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998; 6:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz A, Epelman S, Anelli A, et al. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 1995; 121:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilgard P, Burkert H. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 1984; 20:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goren MP, Houle JM, Bush DA, et al. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 1998; 4:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goren MP, Anthony LB, Hande KR, et al. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 1998; 16:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goren MP, McKenna LM, Goodman TL. Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 1997; 40:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stofer-Vogel B, Cerny T, Borner M, Lauterburg BH. Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol 1993; 32:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mace JR, Keohan ML, Bernardy H, et al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 2003; 9:5829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd JD, Pringle LE, Barnett MJ, et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9:2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballen KK, Becker P, Levebvre K, et al. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients. Oncology 1999; 57:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hows JM, Mehta A, Ward L, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer 1984; 50:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lima MV, Ferreira FV, Macedo FY, et al. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol 2007; 59:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannigan EV, Dinh TV, Doherty MG. Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease. Gynecol Oncol 1991; 43:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm 1997; 54:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava A, Nair SC, Srivastava VM, et al. Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. Bone Marrow Transplant 1999; 23:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy M, Bruninga K, Mutlu EA, et al. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. Am J Gastroenterol 2001; 96:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnston D, Schurtz E, Tourville E, et al. Risk Factors Associated with Severity and Outcomes in Pediatric Patients with Hemorrhagic Cystitis. J Urol 2016; 195:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan JR, Wolf JS Jr. Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis. J Urol 2009; 181:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu J, Xue B, Shan Y, et al. Transurethral coagulation for radiation-induced hemorrhagic cystitis using Greenlight™ potassium-titanyl-phosphate laser. Photomed Laser Surg 2013; 31:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushik D, Teply BA, Hemstreet GP 3rd. Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser. Lasers Med Sci 2012; 27:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez DR, Ercole CE, Lopez JG, et al. A Novel Approach for the Treatment of Radiation-Induced Hemorrhagic Cystitis with the GreenLightTM XPS Laser. Int Braz J Urol 2015; 41:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascoe C, Christidis D, Manning TG, et al. Photoselective Vaporization of the Bladder for the Management of Radiation Cystitis-Technique and Initial Outcomes. Urology 2019; 123:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vicente Rodríguez J, Fariña LA. [Intestinal perforation after treatment of radiation cystitis using the neodymium:YAG laser]. Actas Urol Esp 1991; 15:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westerman ME, Boorjian SA, Linder BJ. Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: A contemporary evaluation. Int Braz J Urol 2016; 42:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goel AK, Rao MS, Bhagwat AG, et al. Intravesical irrigation with alum for the control of massive bladder hemorrhage. J Urol 1985; 133:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostroff EB, Chenault OW Jr. Alum irrigation for the control of massive bladder hemorrhage. J Urol 1982; 128:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella M, Brown E. Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis 1993; 21:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy CP, Cox RL, Harden EA, et al. Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 1992; 10:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seear MD, Dimmick JE, Rogers PC. Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. Urology 1990; 36:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts NB, Williams P. Serum aluminium measurement by DC plasma emission spectrometry. Ann Clin Biochem 1988; 25 ( Pt 2):169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goswami AK, Mahajan RK, Nath R, Sharma SK. How safe is 1% alum irrigation in controlling intractable vesical hemorrhage? J Urol 1993; 149:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abt D, Bywater M, Engeler DS, Schmid HP. Therapeutic options for intractable hematuria in advanced bladder cancer. Int J Urol 2013; 20:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNicol GP, Fletcher AP, Alkjaersig N, Sherry S. The absorption, distribution, and excretion of ϵ-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanini M, English HA, Taylor AE. Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract. J Urol 1990; 143:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh I, Laungani GB. Intravesical epsilon aminocaproic acid in management of intractable bladder hemorrhage. Urology 1992; 40:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye JD, Smith EA, Kirsch AJ, et al. Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. J Urol 2010; 184:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery BD, Boorjian SA, Ziegelmann MJ, et al. Intravesical silver nitrate for refractory hemorrhagic cystitis. Turk J Urol 2016; 42:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghavaiah NV, Soloway MS. Anuria following silver nitrate irrigation for intractable bladder hemorrhage. J Urol 1977; 118:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neovius EB, Lind MG, Lind FG. Hyperbaric oxygen therapy for wound complications after surgery in the irradiated head and neck: a review of the literature and a report of 15 consecutive patients. Head Neck 1997; 19:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cianci P, Sato R. Adjunctive hyperbaric oxygen therapy in the treatment of thermal burns: a review. Burns 1994; 20:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bevers RF, Bakker DJ, Kurth KH. Hyperbaric oxygen treatment for haemorrhagic radiation cystitis. Lancet 1995; 346:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss JP, Boland FP, Mori H, et al. Treatment of radiation-induced cystitis with hyperbaric oxygen. J Urol 1985; 134:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathews R, Rajan N, Josefson L, et al. Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis. J Urol 1999; 161:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 2005; 65:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliai C, Fisher B, Jani A, et al. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys 2012; 84:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oscarsson N, Arnell P, Lodding P, et al. Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol Biol Phys 2013; 87:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida T, Kawashima A, Ujike T, et al. Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. Int J Urol 2008; 15:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mougin J, Souday V, Martin F, et al. Evaluation of Hyperbaric Oxygen Therapy in the Treatment of Radiation-induced Hemorrhagic Cystitis. Urology 2016; 94:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oscarsson N, Müller B, Rosén A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol 2019; 20:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardinal J, Slade A, McFarland M, et al. Scoping Review and Meta-analysis of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis. Curr Urol Rep 2018; 19:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dellis A, Papatsoris A, Kalentzos V, et al. Hyberbaric oxygen as sole treatment for severe radiation - induced haemorrhagic cystitis. Int Braz J Urol 2017; 43:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shao Y, Lu GL, Shen ZJ. Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis. BJU Int 2012; 109:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gil KM, Pugh SL, Klopp AH, et al. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecol Oncol 2019; 154:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umbehr MH, Bachmann LM, Poyet C, et al. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. Health Qual Life Outcomes 2018; 16:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup. J Urol 1998; 160:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur D, Khan SP, Rodriguez V, et al. Hyperbaric oxygen as a treatment modality in cyclophosphamide-induced hemorrhagic cystitis. Pediatr Transplant 2018; 22:e13171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajith Kumar S, Prasanth P, Tripathi K, Ghosh P. Hyperbaric oxygen-A new horizon in treating cyclophosphamide-induced hemorrhagic cystitis. Indian J Urol 2011; 27:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hampson SJ, Woodhouse CR. Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: experience with 14 patients. Eur Urol 1994; 25:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhu SS, Goldstraw M, Woodhouse CR. The management of haemorrhagic cystitis with sodium pentosan polysulphate. BJU Int 2004; 94:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toren PJ, Norman RW. Cyclophosphamide induced hemorrhagic cystitis successfully treated with pentosanpolysulphate. J Urol 2005; 173:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YK, Harty JI, Steinbock GS, et al. Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen. J Urol 1990; 144:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller J, Burfield GD, Moretti KL. Oral conjugated estrogen therapy for treatment of hemorrhagic cystitis. J Urol 1994; 151:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ordemann R, Naumann R, Geissler G, et al. Encouraging results in the treatment of haemorrhagic cystitis with estrogen - report of 10 cases and review of the literature. Bone Marrow Transplant 2000; 25:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopterides P, Theodorakopoulou M, Mentzelopoulos S, Armaganidis A. Cyclophosphamide-induced hemorrhagic cystitis successfully treated with conjugated estrogens. Am J Hematol 2005; 80:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mousavi SA, Moazed V, Mohebbi N, et al. Conjugated Estrogen in Late-Onset Hemorrhagic Cystitis Associated with Hematopoietic Stem Cell Transplantation. Int J Hematol Oncol Stem Cell Res 2017; 11:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geisler JP, Linnemeier GC, Manahan KJ. Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis: a case report. J Reprod Med 2008; 53:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashrani AA, Gabriel DA, Gajewski JL, et al. Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplant 2006; 38:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3:1935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karimi M, Zakerinia M, Khojasteh HN, et al. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2004; 2:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001; 28:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sneiders A, Pryor JL. Percutaneous nephrostomy drainage in the treatment of severe hemorrhagic cystitis. J Urol 1993; 150:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zagoria RJ, Hodge RG, Dyer RB, Routh WD. Percutaneous nephrostomy for treatment of intractable hemorrhagic cystitis. J Urol 1993; 149:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shrom SH, Donaldson MH, Duckett JW, Wein AJ. Formalin treatment for intractable hemorrhagic cystitis: a review of the literature with 16 additional cases. Cancer 1976; 38:1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vicente J, Rios G, Caffaratti J. Intravesical formalin for the treatment of massive hemorrhagic cystitis: retrospective review of 25 cases. Eur Urol 1990; 18:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewan AK, Mohan GM, Ravi R. Intravesical formalin for hemorrhagic cystitis following irradiation of cancer of the cervix. Int J Gynaecol Obstet 1993; 42:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahue LA, Frank IN. Intravesical formalin for hemorrhagic cystitis: analysis of therapy. J Urol 1989; 141:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegelmann MJ, Boorjian SA, Joyce DD, et al. Intravesical formalin for hemorrhagic cystitis: A contemporary cohort. Can Urol Assoc J 2017; 11:E79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fair WR. Formalin in the treatment of massive bladder hemorrhage. Techniques, results, and complications. Urology 1974; 3:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottesman J, Ehrlich RM. Preventing vesicoureteral reflux during intravesical formalin instillation. Urology 1974; 3:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han Y, Wu D, Sun A, et al. Selective embolization of the internal iliac arteries for the treatment of severe hemorrhagic cystitis following hematopoietic SCT. Bone Marrow Transplant 2008; 41:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giné E, Rovira M, Real I, et al. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant 2003; 31:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Berardinis E, Vicini P, Salvatori F, et al. Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrhage. Int J Urol 2005; 12:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasumura K, Ikegami K, Kamohara T, Nohara Y. High incidence of ischemic necrosis of the gluteal muscle after transcatheter angiographic embolization for severe pelvic fracture. J Trauma 2005; 58:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieber PR. Bladder necrosis secondary to pelvic artery embolization: case report and literature review. J Urol 1994; 151:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder BJ, Tarrell RF, Boorjian SA. Cystectomy for refractory hemorrhagic cystitis: contemporary etiology, presentation and outcomes. J Urol 2014; 192:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noe HN, McSwain HM. Management of severe reflux in the patient with cyclophosphamide cystitis. J Urol 1983; 130:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh FP, Vince FP, Pollock DJ, Blandy JP. Cyclophosphamide necrosis of bladder causing calcification, contracture and reflux; treated by colocystoplasty. Br J Urol 1971; 43:324.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2829 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9106019" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hemorrhagic cystitis as a complication of bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8134990" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Urologic complications of high-dose chemotherapy and bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7308258" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37501638" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Haemorrhagic cystitis: a review of management strategies and emerging treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14486208" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cyclophosphamide and urinary bladder toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/510344" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cyclophosphamide cystitis and bladder cancer. A hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634459" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Involvement of nitric oxide and hyperbaric oxygen in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9006340" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821589" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17225077" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17225077" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4837137" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4614898" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical trial of isophosphamide (NSC-109724)--results and side effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4552918" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Unexpected toxicity in patients treated with iphosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3286879" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ifosfamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1261795" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1277220" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3107815" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Phase II trial of ifosfamide and mesna in advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6414700" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6438851" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19018081" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506637" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12065567" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3896483" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ifosfamide--pharmacology, safety and therapeutic potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10637075" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21972971" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Low-dose cyclophosphamide associated with hemorrhagic cystitis in a breast cancer patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28744217" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26168069" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1059500" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2864573" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : BK virus as cause of haemorrhagic cystitis after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2551434" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23103682" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Recipient seropositivity for adenovirus type 11 (AdV11) is a highly predictive factor for the development of AdV11-induced hemorrhagic cystitis after allogeneic hematopoietic SCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21498717" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7738616" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3014334" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18854779" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24322335" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hemorrhagic radiation cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20212517" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Management of radiation cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7959285" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635768" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29594221" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: A 10-year follow-up study of genitourinary toxicity in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24113055" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17967304" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21425143" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15752881" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864217" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Urologic emergencies in the cancer patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12137633" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403595" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Hemorrhagic cystitis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26271398" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4775738" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Urological complications of cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6576177" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Busulfan-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7269015" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Busulfan-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32698717" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Microhematuria: AUA/SUFU Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6255715" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Identification of viruses in the urine of renal transplant recipients by cytomorphology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6251715" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Activation of human polyomavirus infection-detection by cytologic technics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26936410" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3090314" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1909700" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315426" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6106781" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/106965" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6414694" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The development of mesna for regional detoxification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8677458" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9540174" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Use of mesna to prevent ifosfamide-induced urotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7883776" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6437825" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9796960" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9469350" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9272112" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Combined intravenous and oral mesna in outpatients treated with ifosfamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8462128" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Oral bioavailability of mesna tablets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14676103" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1941060" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10575313" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6437430" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16947012" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1743553" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7973776" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9099346" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Amifostine for protection from antineoplastic drug toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783663" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Cytoprotective agents for anthracyclines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10100560" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829154" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316150" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26926552" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Risk Factors Associated with Severity and Outcomes in Pediatric Patients with Hemorrhagic Cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19091348" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23327634" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Transurethral coagulation for radiation-induced hemorrhagic cystitis using Greenlight™potassium-titanyl-phosphate laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370618" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26200555" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A Novel Approach for the Treatment of Radiation-Induced Hemorrhagic Cystitis with the GreenLightTM XPS Laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29777786" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Photoselective Vaporization of the Bladder for the Management of Radiation Cystitis-Technique and Initial Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1807127" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : [Intestinal perforation after treatment of radiation cystitis using the neodymium:YAG laser].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27509371" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: A contemporary evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3999219" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Intravesical irrigation with alum for the control of massive bladder hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7176055" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Alum irrigation for the control of massive bladder hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8418625" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Acute aluminum toxicity and alum bladder irrigation in patients with renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1422497" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Encephalopathy and seizures induced by intravesical alum irrigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2219619" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3382147" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Serum aluminium measurement by DC plasma emission spectrometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8426397" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : How safe is 1% alum irrigation in controlling intractable vesical hemorrhage?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23387805" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Therapeutic options for intractable hematuria in advanced bladder cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The absorption, distribution, and excretion ofϵ-aminocaproic acid following oral or intravenous administration to man
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2304169" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1523745" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Intravesical epsilon aminocaproic acid in management of intractable bladder hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20650477" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27635296" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Intravesical silver nitrate for refractory hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/916077" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Anuria following silver nitrate irrigation for intractable bladder hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9213110" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Hyperbaric oxygen therapy for wound complications after surgery in the irradiated head and neck: a review of the literature and a report of 15 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8148076" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Adjunctive hyperbaric oxygen therapy in the treatment of thermal burns: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7674746" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Hyperbaric oxygen treatment for haemorrhagic radiation cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4020991" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Treatment of radiation-induced cystitis with hyperbaric oxygen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915420" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15833500" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22440041" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24035333" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18643783" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27125879" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Evaluation of Hyperbaric Oxygen Therapy in the Treatment of Radiation-induced Hemorrhagic Cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31537473" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29654564" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Scoping Review and Meta-analysis of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28338304" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Hyberbaric oxygen as sole treatment for severe radiation - induced haemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21895939" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31104905" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29458434" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9720533" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29569791" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Hyperbaric oxygen as a treatment modality in cyclophosphamide-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21814321" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Hyperbaric oxygen-A new horizon in treating cyclophosphamide-induced hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7508397" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: experience with 14 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15476520" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : The management of haemorrhagic cystitis with sodium pentosan polysulphate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15592042" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Cyclophosphamide induced hemorrhagic cystitis successfully treated with pentosanpolysulphate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2162975" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8158784" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Oral conjugated estrogen therapy for treatment of hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10800067" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Encouraging results in the treatment of haemorrhagic cystitis with estrogen - report of 10 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16184578" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Cyclophosphamide-induced hemorrhagic cystitis successfully treated with conjugated estrogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28286609" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Conjugated Estrogen in Late-Onset Hemorrhagic Cystitis Associated with Hematopoietic Stem Cell Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18567283" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133240" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16102099" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15456505" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11571515" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8345621" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Percutaneous nephrostomy drainage in the treatment of severe hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8501785" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Percutaneous nephrostomy for treatment of intractable hemorrhagic cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/991094" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Formalin treatment for intractable hemorrhagic cystitis: a review of the literature with 16 additional cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2261933" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Intravesical formalin for the treatment of massive hemorrhagic cystitis: retrospective review of 25 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7901061" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Intravesical formalin for hemorrhagic cystitis following irradiation of cancer of the cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2648027" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Intravesical formalin for hemorrhagic cystitis: analysis of therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360951" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Intravesical formalin for hemorrhagic cystitis: A contemporary cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4830634" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Formalin in the treatment of massive bladder hemorrhage. Techniques, results, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4822701" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Preventing vesicoureteral reflux during intravesical formalin instillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18246111" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Selective embolization of the internal iliac arteries for the treatment of severe hemorrhagic cystitis following hematopoietic SCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748670" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948754" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15920413" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : High incidence of ischemic necrosis of the gluteal muscle after transcatheter angiographic embolization for severe pelvic fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8283543" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Bladder necrosis secondary to pelvic artery embolization: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24936722" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Cystectomy for refractory hemorrhagic cystitis: contemporary etiology, presentation and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6887415" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Management of severe reflux in the patient with cyclophosphamide cystitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4933887" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Cyclophosphamide necrosis of bladder causing calcification, contracture and reflux; treated by colocystoplasty.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
